- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01724736
A Pilot Study to Determine the Effect of a Cobiotic Formulation on the Gastrointestinal Microbiome
July 23, 2014 updated by: NuMe Health
A Pilot Study to Determine the Effect of a Cobiotic Formulation on the Fecal Bacteroidetes: Firmicutes Ratio in Pre-Diabetic Subjects.
This study aims to investigate the effect of a cobiotic formulation, prepared as a smoothie beverage, on the ratio of intestinal microbiota of the Bacteroidetes phylum to those of the Firmicutes phylum in the stool as well as the effect on insulin resistance, gut hormones (PYY) Peptide YY and (GLP-1) Glucagon-like Peptide, ghrelin with perceptions of appetite and satiety.
Study Overview
Detailed Description
Human gut microbiome appears to be involved in the regulation of metabolic processes, including digested food components, absorption of fat, metabolism of drugs, and conversion of indigestible foods or partially digested food ingredients to molecules that may signal physiological host mechanisms.
The gut microbiome is a complex ecosystem of liquor or chime and microbiota.
A change in that habitat may result in microbiota community shifts and consequential changes in brain-gut regulatory interactions.
NM504 is a cobiotic formulation composed of 3 (generally recognized as safe; GRAS) food ingredients.
One ingredient is a conventional prebiotic fiber.
A second ingredient can be fermented but it also is included to change the viscosity of the biome while protecting the mucosal barrier.
The 3rd ingredient is an antioxidant with poor bioavailability that alters the redox potential of the biome, selecting for some and against other microbiota growth.
In a placebo-controlled double-blinded intervention this trial will investigate the effect of NM504 on the intestinal microbiota as well as markers of glucose regulation in 20 prediabetic adults.
The intervention periods last 28 days.
Examination of participants will happen at the beginning, weekly and at the end of intervention and will contain anthropometry; blood samples; fecal samples; oral glucose tolerance test; meal tolerance test; and scales to assess appetite, hunger, mood, and bowel habits.
Study Type
Interventional
Enrollment (Anticipated)
45
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70808
- Pennington Biomedical Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy male or female.
- Stable body weight.
- Stable body weight (+ 11 pounds) in the 3 months prior to the study. Between 18 and 70 years of age, inclusive.
- BMI between 25 and 45 Kg/m2, inclusive. BMI is a measure of your height to weight ratio. (Body Mass Index).
- Fasting blood glucose between 100 and 200 mg/dL, inclusive.
Exclusion Criteria:
- Pregnant or nursing.
- Diabetes or diseases of the liver, pancreas or gastrointestinal tract (except surgery like cholecystectomy, appendectomy or hiatus hernia repair).
- Taking a medication for diabetes, or a medication like systemic glucocorticoids that can affect blood insulin, or a mediation like atypical antipsychotics that alters affect blood sugar or blood insulin, or a medication like atypical antipsychotics that alters body weight, or a medication like antibiotics that can change intestinal bacterial flora, or a medication that alters blood lipids.
- Past history of Bariatric surgery.
- Chronic use of proton pump inhibitors or bulk laxatives.
- Active dependence on alcohol (>14 drinks/week) or illegal drugs.
- following a weight loss regimen.
- Body weight over 350 pounds (.160 kg).
- Any chronic medication [for example: for treatment of conditions like hypothyroidism (like thyroxine), gout (like allopurinol) or hypertension (like propranolol)] that has not had a stable dose for 1 month or longer.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo Comparator:
Celluose 10g - Matches the total dietary fiber content of NM504 as well as the color and taste.
Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
|
Celluose 10g - Matches the total dietary fiber content of NM504 as well as the color and taste.
Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
Cobiotic formula of GRAS ingredients with a total dietary fiber content of 10g.
Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
|
Active Comparator: NM504:
Cobiotic formula of GRAS ingredients with a total dietary fiber content of 10g.
Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
|
Celluose 10g - Matches the total dietary fiber content of NM504 as well as the color and taste.
Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
Cobiotic formula of GRAS ingredients with a total dietary fiber content of 10g.
Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the ratio of Bacteroidetes to Firmicuites ratio in the stool comparing the baseline value to the completion of study value.
Time Frame: 4 weeks
|
Abundance of 11 different genera that are characterized in lean and obese individuals will be quantitated and the ratio of abundance of those in the Bacteriodetes phylum to Firmicutes phylum will calculated.
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Insulin sensitivity based on homeostasis model assessment (HOMA)
Time Frame: 4 weeks
|
Fasting blood glucose and insulin levels will be used to calculate HOMA-IR (insulin resistance) and to estimate insulin sensitivity at baseline and at the completion of the study.
|
4 weeks
|
Fasting blood glucose
Time Frame: Weekly for 4 weeks
|
Weekly measurements of fasting blood glucose and serum insulin will be performed.
|
Weekly for 4 weeks
|
Body weight
Time Frame: Weekly for 4 weeks
|
Body weight will be monitored weekly.
|
Weekly for 4 weeks
|
Hunger perception
Time Frame: Weekly for 4 weeks
|
Visual analog scales to assess appetite and satiety will be used at weekly visits.
|
Weekly for 4 weeks
|
Meal tolerance test
Time Frame: 3 weeks
|
A fixed meal will be consumed at 3 weeks.
Visual analog scales (VAS) for appetite will be used to measure hunger before the meal.
A VAS to assess satiety will be used at completion of the meal.
Plasma ghrelin, PYY, GLP-1, glucose and insulin will be measured both before the meal and at 1 hour after consumption.
|
3 weeks
|
Clinical Chemistry
Time Frame: 4 weeks
|
Blood will be obtained at baseline and after 4-weeks of treatment to measure lipids, high-sensitivity C-reactive protein (hsCRP) and glycosylated hemoglobin (HgbA1c).
|
4 weeks
|
Fecal profiling
Time Frame: 4 weeks
|
Feces will be collected at baseline and after 4 weeks to measure pH, short chain fatty acids, pathogens, branched chain fatty acids and triglycerides to assess changes in the GI microbiome.
|
4 weeks
|
Insulin sensitivity based on Oral Glucose Tolerance Testing
Time Frame: 4 weeks
|
An oral glucose tolerance test will be performed at baseline and at the completion of the study to estimate insulin sensitivity.
|
4 weeks
|
Mood
Time Frame: 4 weeks
|
A standardized mood instrument will be used at baseline and at 4 weeks.
|
4 weeks
|
Gastrointestinal Symptoms
Time Frame: 4 weeks
|
A survey to measure GI symptoms, changes in bowel habits and changes in stool characteristics will be performed on weekly visits for 4 weeks.
|
4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2012
Primary Completion (Actual)
February 1, 2014
Study Completion (Actual)
February 1, 2014
Study Registration Dates
First Submitted
November 6, 2012
First Submitted That Met QC Criteria
November 9, 2012
First Posted (Estimate)
November 12, 2012
Study Record Updates
Last Update Posted (Estimate)
July 24, 2014
Last Update Submitted That Met QC Criteria
July 23, 2014
Last Verified
July 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PrCo Study
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pre Diabetic
-
Mayo ClinicTerminated
-
University of California, San FranciscoCompletedPhysical Activity | Sedentary Lifestyle | Pre-DiabeticUnited States
-
Ottawa Heart Institute Research CorporationCompletedPre-diabetic | Diabetic Type II MellitusCanada
-
The Cleveland ClinicNestléCompletedObesity | Overweight | Pre-diabeticUnited States
-
University of North Carolina, Chapel HillCompletedObesity | Overweight | Pre-DiabeticUnited States
-
University of California, Los AngelesCompleted
-
Huazhong University of Science and TechnologyUnknown
-
Nantes University HospitalCompleted
-
Vanderbilt UniversityCompletedHealthy | Pre-diabetic
-
Universitaet InnsbruckMedical University InnsbruckCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States